Research Article
[Retracted] Efficacy Evaluation of Inflammatory Mediators in the Treatment of Multiple Myeloma with Daratumumab
Table 1
Disease characteristics of enrolled patients.
| | Experimental group | Control group |
| Gender | 2 : 5 | 7 : 7 | Age | Age 52–81 (average 65) | Age 51–82 (average 68) | DS staging ratio (I : II : III) | 0 : 0 : 100% | 0 : 0 : 100% | ISS staging ratio (I : II : III) | 1 : 4:2 | 1 : 5 : 8 | R-ISS staging ratio (I : II : III) | 0 : 1:6 | 1 : 6 : 7 | SMART staging (standard risk: high risk) | 1 : 6 | 10 : 4 |
|
|